APA (7th ed.) Citation

JH, L., SH, K., HR, K., CK, M., JJ, L., HJ, S., . . . K, K. (2023). Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. International journal of hematology, 117(2), 225. https://doi.org/10.1007/s12185-022-03479-6

Chicago Style (17th ed.) Citation

JH, Lee, et al. "Real-world Toxicity and Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Korean Patients with Relapsed And/or Refractory Multiple Myeloma." International Journal of Hematology 117, no. 2 (2023): 225. https://doi.org/10.1007/s12185-022-03479-6.

MLA (9th ed.) Citation

JH, Lee, et al. "Real-world Toxicity and Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Korean Patients with Relapsed And/or Refractory Multiple Myeloma." International Journal of Hematology, vol. 117, no. 2, 2023, p. 225, https://doi.org/10.1007/s12185-022-03479-6.